-
The innate power of natural killer cells in cancer therapy Nat. Med. (IF 58.7) Pub Date : 2025-05-12 Ebba Sohlberg, Karl-Johan Malmberg
-
The Microbiome and Cancer: A Translational Science Review. JAMA (IF 63.1) Pub Date : 2025-05-12 Estefania Fernandez,Jennifer A Wargo,Beth A Helmink
Importance Growing evidence suggests that microbes located within the gastrointestinal tract and other anatomical locations influence the development and progression of diseases such as cancer. Observations Clinical and preclinical evidence suggests that microbes in the gastrointestinal tract and other anatomical locations, such as the respiratory tract, may affect carcinogenesis, development of metastases
-
Oral Glucose-Lowering Agents and Large-for-Gestational-Age Infants in Gestational Diabetes. JAMA (IF 63.1) Pub Date : 2025-05-12 Chao Su
-
Changes in Physical and Mental Health After the End of SNAP Emergency Allotments. JAMA (IF 63.1) Pub Date : 2025-05-12 Michael Liu,Daniel Y Johnson,Sara N Bleich,Prihatha R Narasimmaraj,Camilla Bjorck-Posson,Jose F Figueroa,Rishi K Wadhera
-
Antihypertensive Medication Timing and Cardiovascular Events and Death: The BedMed Randomized Clinical Trial. JAMA (IF 63.1) Pub Date : 2025-05-12 Scott R Garrison,Jeffrey A Bakal,Michael R Kolber,Christina S Korownyk,Lee A Green,Jessica E M Kirkwood,Finlay A McAlister,Raj S Padwal,Richard Lewanczuk,Michael D Hill,Alexander G Singer,Alan Katz,Michael D Kelmer,Armine Gayayan,Farah N Campbell,Ana Vucenovic,Nathan R Archibald,Jack M S Yeung,Erik R E Youngson,Kimberlyn McGrail,Braden G O'Neill,Michelle Greiver,Donna P Manca,Roni Y Kraut,Ting Wang
Importance Whether administration of blood pressure medications at bedtime instead of in the morning reduces cardiovascular risk is unknown, as findings from large clinical trials have not been consistent. There is also concern that bedtime antihypertensive use could induce glaucoma-related visual loss or other hypotensive/ischemic adverse effects. Objective To determine the effect of bedtime vs morning
-
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N. Engl. J. Med. (IF 96.2) Pub Date : 2025-05-11 Louis J Aronne,Deborah Bade Horn,Carel W le Roux,Wayne Ho,Beverly L Falcon,Elisa Gomez Valderas,Sagar Das,Clare J Lee,Leonard C Glass,Cagri Senyucel,Julia P Dunn,
BACKGROUND Tirzepatide and semaglutide are highly effective medications for obesity management. The efficacy and safety of tirzepatide as compared with semaglutide in adults with obesity but without type 2 diabetes is unknown. METHODS In this phase 3b, open-label, controlled trial, adult participants with obesity but without type 2 diabetes were randomly assigned in a 1:1 ratio to receive the maximum
-
UK decision not to suppress covid raises questions about medical and scientific advice. BMJ (IF 93.6) Pub Date : 2025-05-11 Anthony Costello
-
Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole (MIROCALS): a phase 2b, double-blind, randomised, placebo-controlled trial Lancet (IF 98.4) Pub Date : 2025-05-09 Gilbert Bensimon, P Nigel Leigh, Timothy Tree, Andrea Malaspina, Christine AM Payan, Hang-Phuong Pham, Pieter Klaassen, Pamela J Shaw, Ahmad Al Khleifat, Maria D M Amador, Shahram Attarian, Simon M Bell, Stéphane Beltran, Emilien Bernard, William Camu, Philippe Corcia, Jean-Christophe Corvol, Philippe Couratier, Véronique Danel, Rabab Debs, Ammar Al-Chalabi
BackgroundAmyotrophic lateral sclerosis (ALS) is a life-threatening disease characterised by progressive loss of motor neurons with few therapeutic options. The MIROCALS study tested the hypothesis that low-dose interleukin-2 (IL-2LD) improves survival and function in ALS. MethodsIn this randomised, double-blind, placebo-controlled trial, male and female riluzole-naive participants, with either a possible
-
Examining the evidence for IL-2 in amyotrophic lateral sclerosis Lancet (IF 98.4) Pub Date : 2025-05-09 Michael Benatar, Michael P McDermott
No Abstract
-
Reducing the burden of chronic kidney disease in the world Lancet (IF 98.4) Pub Date : 2025-05-09 Randall Lou-Meda, Joaquín Barnoya Pérez
No Abstract
-
AI-Driven Clinical Documentation - Driving Out the Chitchat? N. Engl. J. Med. (IF 96.2) Pub Date : 2025-05-10 Gordon D Schiff
-
Sixty Years of Community Health Centers - An Anniversary at a Crossroads. N. Engl. J. Med. (IF 96.2) Pub Date : 2025-05-10 Alexander E Jacobs
-
Livebirth rates significantly lower among women diagnosed with cancer CA: Cancer J. Clin. (IF 503.1) Pub Date : 2025-05-08 Carrie Printz
Women who are diagnosed with cancer during their reproductive years have significantly fewer livebirths than those without cancer, according to a Danish registry-based cohort study. Researchers found that livebirth rates after a cancer diagnosis increasingly declined with age and varied with specific cancers. The rates of a first livebirth after cancer were lowest among women with leukemia, breast
-
Issue Information CA: Cancer J. Clin. (IF 503.1) Pub Date : 2025-05-08
No abstract is available for this article.
-
Active monitoring of DCIS shows promise in short-term study CA: Cancer J. Clin. (IF 503.1) Pub Date : 2025-05-08 Carrie Printz
“The results are very provocative in terms of turning the assumption that we’ve always had on its head, and that’s why it’s such an important study—because it challenges dogma.” —Shelley Hwang, MD, MPH Early results from the first study comparing active monitoring to surgery for patients with low-risk ductal carcinoma in situ (DCIS) support the short-term safety of active monitoring. Researchers released
-
Artificial intelligence improves breast cancer detection in mammography screening Nat. Med. (IF 58.7) Pub Date : 2025-05-09
-
Three decades of global dietary iron deficiency trends and disparities across populations Nat. Med. (IF 58.7) Pub Date : 2025-05-09
-
-
US AI regulatory rollback and health Lancet (IF 98.4) Pub Date : 2025-05-08 Paul Webster
No Abstract
-
Trump works towards US tariffs on drug imports Lancet (IF 98.4) Pub Date : 2025-05-08 Susan Jaffe
No Abstract
-
Intimate partner violence and ART adherence in Uganda Lancet (IF 98.4) Pub Date : 2025-05-08 Josephine Nabayinda, Samuel Kizito, Fred M Ssewamala, Mary McKay
No Abstract
-
Triple crisis among refugee youth resettled in high-income countries Lancet (IF 98.4) Pub Date : 2025-05-08 Nhial T Tutlam, Nyabang Buom, Samuel Kizito, Salma Abdalla
No Abstract
-
The Changing Mindsets Initiative Lancet (IF 98.4) Pub Date : 2025-05-08 Abdul Ghaffar, Seye Abimbola, Ren Minghui, Jesse Uneke, Rhoda Wanyenze, Srinath Reddy
No Abstract
-
Safety of intranasally administered etripamil: RAPID trial update Lancet (IF 98.4) Pub Date : 2025-05-08 Bruce S Stambler, A John Camm, Jonathan P Piccini, David B Bharucha, James E Ip
No Abstract
-
Positive RPR and TPLA tests cannot confirm congenital syphilis Lancet (IF 98.4) Pub Date : 2025-05-08 Xin Yu Yang, Gong Jie Zhang, Ya Bin Zhou
No Abstract
-
Positive RPR and TPLA tests cannot confirm congenital syphilis – Authors' reply Lancet (IF 98.4) Pub Date : 2025-05-08 Tomoaki Hirate, Kunihiro Shinoda, Nobuyuki Tetsuka
No Abstract
-
Isotretinoin-associated cervical osteophytosis Lancet (IF 98.4) Pub Date : 2025-05-08 Huang Chang-Quan
No Abstract
-
Isotretinoin-associated cervical osteophytosis – Authors' reply Lancet (IF 98.4) Pub Date : 2025-05-08 Kamran Naraghi, Helena Marzo-Ortega
No Abstract
-
Department of Error Lancet (IF 98.4) Pub Date : 2025-05-08
Bossi A, Foulon S, Maldonado X, et al. Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2?×?2 factorial design. Lancet 2024; 404: 2065–76—In this Article, the affiliations for Fabio Calabro should have included “IRCCS National Cancer Institute Regina Elena, Rome, Italy”. This
-
Postnatal wards should nurture new mothers, not heighten their vulnerability BMJ (IF 93.6) Pub Date : 2025-05-09 Alice Giucca
Alice Giucca describes how her experience on a postnatal ward showed a system in collapse As I watch my newborn daughter sleep in one of her three hour stretches of peaceful bliss, I do what I have been conditioned to do throughout my medical career: I reflect. As is often the case with birth, my daughter’s arrival did not go to plan, spiralling terrifyingly quickly from a state of calm to intrapartum
-
We should implement electronic blood management systems across the UK to improve blood transfusion safety BMJ (IF 93.6) Pub Date : 2025-05-09 Mark Vickers, Michael Murphy, Roger Graham, James Neuberger
A recent report from the Infected Blood Inquiry (IBI) brought again to professional and public attention the risks and potential harm that may be associated with blood transfusion. The report made many recommendations to improve the safety of blood transfusion.1 Public attention focused on the harm that so many people experienced and the decision making processes that led to the failures of care. But
-
See one, do one, teach one: other professionals don’t accept this so why should the medical profession? BMJ (IF 93.6) Pub Date : 2025-05-09 Grainne P Kearney, Nick Gardiner, Davina Carr, Martina Kelly, Gerard J Gormley
Throughout medical school and as teaching clinicians we are frequently reminded how the word doctor originates from the Latin docere —to teach. Teaching, for doctors, is considered an innate “competency,” genetically part of our DNA. Participation in teaching is a standard inclusion in the job description. Baked into this truism is a further expectation—that because we work as doctors, we can automatically
-
Sunil Krishnalal Pandya BMJ (IF 93.6) Pub Date : 2025-05-09 Sanjay Pai
Sunil Pandya was born and spent almost his entire life in Bombay (now Mumbai). He joined Grant Medical College in 1957, graduating in 1961. He then gained a masters in general surgery and trained in neurosurgery. In 1968 he joined a public hospital, King Edward VII Memorial Hospital, and Seth Gordhandas Sunderdas Medical College (KEM-GSMC) where he worked with Homi Dastur. In 1974-75 he spent a year
-
John Grayson Grounds BMJ (IF 93.6) Pub Date : 2025-05-09 Michael Grounds
John was born in London, then moved to Sheffield and North Wales, where he attended Penygroes Secondary School. He qualified from St Andrew’s in 1947 and undertook his pre-registration year at the University Hospital in Dundee. On completion he was called up for national service and became a medical officer in the Black Watch; he was sent through Egypt to serve with the 2nd King’s African Rifles in
-
RANO criteria for response assessment of brain metastases based on amino acid PET imaging Nat. Med. (IF 58.7) Pub Date : 2025-05-08 Nathalie L. Albert, Norbert Galldiks, Benjamin M. Ellingson, Martin J. van den Bent, Susan M. Chang, Francesco Cicone, Eng-Siew Koh, Ian Law, Emilie Le Rhun, Maximilian J. Mair, Jan-Michael Werner, Anna S. Berghoff, Julia Furtner, Giuseppe Minniti, Andrew M. Scott, Susan C. Short, Jana Ivanidze, Derek R. Johnson, Bogdana Suchorska, Nelleke Tolboom, Joerg-Christian Tonn, Antoine Verger, Eva Galanis
-
What does your patient think about AI in the NHS? BMJ (IF 93.6) Pub Date : 2025-05-09 Mun-Keat Looi
At a recent conference in London patients gave an insight into their thoughts on use of AI in the NHS Artificial intelligence is no longer a futuristic fantasy; it’s rapidly becoming a part of our everyday lives, including the healthcare sector. But as with any technological advance in healthcare its integration comes with its own set of challenges and considerations. Speaking at an NHS conference
-
How do I deal with a colleague who’s been inappropriate towards me? BMJ (IF 93.6) Pub Date : 2025-05-09 Tom Moberly
Many doctors experience distressing inappropriate behaviour from colleagues, including unwelcome sexual comments and advances. Tom Moberly hears advice on how to tackle such behaviour Chelcie Jewitt, cofounder of Surviving in Scrubs,1 says, “The first piece of advice I would give to anyone in this situation is to look after yourself. There is an onus on you to speak up when things happen, but in real
-
Efruxifermin in Compensated Liver Cirrhosis Caused by MASH. N. Engl. J. Med. (IF 96.2) Pub Date : 2025-05-09 Mazen Noureddin,Mary E Rinella,Naga P Chalasani,Guy W Neff,K Jean Lucas,Manuel E Rodriguez,Madhavi Rudraraju,Rashmee Patil,Cynthia Behling,Mark Burch,Doreen C Chan,Erik J Tillman,Arian Zari,Brittany de Temple,Reshma Shringarpure,Meena Jain,Timothy Rolph,Andrew Cheng,Kitty Yale
BACKGROUND In phase 2 trials involving patients with stage 2 or 3 fibrosis caused by metabolic dysfunction-associated steatohepatitis (MASH), efruxifermin, a bivalent fibroblast growth factor 21 (FGF21) analogue, reduced fibrosis and resolved MASH. Data are needed on the efficacy and safety of efruxifermin in patients with compensated cirrhosis (stage 4 fibrosis) caused by MASH. METHODS In this phase
-
When I use a word . . . Penicillin during the second world war. BMJ (IF 93.6) Pub Date : 2025-05-09 Jeffrey K Aronson
-
Gates Foundation to shut early, spending $200bn in next two decades. BMJ (IF 93.6) Pub Date : 2025-05-09 Luke Taylor
-
GPs should not be compelled to have a role in assisted dying services, say LMCs. BMJ (IF 93.6) Pub Date : 2025-05-09 Adrian O'Dowd
-
-
Climate emergency: Tony Blair Institute sparks row with call to rethink net zero strategy. BMJ (IF 93.6) Pub Date : 2025-05-09 Dominic Murphy
-
WHO Issues First-Ever Global Meningitis Guidelines. JAMA (IF 63.1) Pub Date : 2025-05-09 Samantha Anderer
-
GLP-1 Medications Overtake Traditional Weight-Loss Drugs. JAMA (IF 63.1) Pub Date : 2025-05-09 Samantha Anderer
-
Hearing Loss Tied to Heart Failure in Part via Emotional Strain. JAMA (IF 63.1) Pub Date : 2025-05-09 Samantha Anderer
-
Yoga Rivals Strength Training for Knee Arthritis Relief. JAMA (IF 63.1) Pub Date : 2025-05-09 Samantha Anderer
-
First Drug for Nonrelapsing MS Progression on the Horizon. JAMA (IF 63.1) Pub Date : 2025-05-09 Samantha Anderer
-
One Million New Pediatric HIV Cases Predicted If PEPFAR Funding Is Cut. JAMA (IF 63.1) Pub Date : 2025-05-09 Samantha Anderer
-
Sense of Smell Is a Marker for Mortality Risk, With Dementia and Frailty as Key Mediators JAMA (IF 63.1) Pub Date : 2025-05-09 Virginia Hunt
This Medical News article highlights recent research into olfactory deficits in older adults and mortality risk, including factors that mediate this relationship.
-
The BMJ Editorial Scholar 2025/2026 BMJ (IF 93.6) Pub Date : 2025-05-08 British Medical Journal Publishing Group
Are you a medical student interested in learning how a medical journal is run? Do you have a passion for creating engaging content for medical students? If so, apply to be The BMJ ’s next editorial scholar. The editorial scholar takes one year out of medical school to work with The BMJ ’s international team of editors and lead BMJ Student , the student section of The BMJ . In this role you will:
-
Effects of a general practitioner-led brief narrative exposure intervention on symptoms of post-traumatic stress disorder after intensive care (PICTURE): multicentre, observer blind, randomised controlled trial BMJ (IF 93.6) Pub Date : 2025-05-07 Jochen Gensichen, Konrad F R Schmidt, Linda Sanftenberg, Robert P Kosilek, Chris M Friemel, Antina Beutel, Johanna Dohmann, Christoph Heintze, Hallie C Prescott, Ulf-Dietrich Reips, Maggie Schauer, Daniela Lindemann, Christian Brettschneider, Tobias Dreischulte, Bernhard Zwi?ler, Thomas Elbert
Objective To determine the effect of a novel brief general practitioner (GP)-led narrative exposure intervention on post-traumatic stress disorder (PTSD) symptoms after intensive care. Design Multicentre, observer blind, randomised controlled trial (PICTURE). Setting Primary care in 319 general practices across Germany. Participants 319 adults (18-85 years) who have survived critical illness with symptoms
-
Culture should be a strategic priority amid the changing landscape of the healthcare system BMJ (IF 93.6) Pub Date : 2025-05-08 Isabelle Brown, policy adviser, Laura Turner, policy officer
The way we treat staff working in the healthcare system is crucial to the success of any reform, say Isabelle Brown and Laura Turner The NHS workforce is under considerable operational pressure at every level from the combined effects of record demand and shortages of capital and resource.1 In addition, seismic shifts are on the horizon, including the abolition of NHS England (NHSE), the expected recommendations
-
Treatment options to support the elimination of hepatitis C: an open-label, factorial, randomised controlled non-inferiority trial Lancet (IF 98.4) Pub Date : 2025-05-08 Graham S Cooke, Le Manh Hung, Barnaby Flower, Leanne McCabe, Vu Thi Kim Hang, Vo Thi Thu, Dang Trong Thuan, Nguyen Thanh Dung, Le Thanh Phuong, Dao Bach Khoa, Nguyen Thi Chau An, Pham Ngoc Thach, Vu Thi Thu Huong, Dang Thi Bich, Nguyen Kim Tuyen, M Azim Ansari, Chau Le Ngoc, Vo Minh Quang, Nguyen Thi Ngoc Phuong, Le Thi Thao, A Sarah Walker
BackgroundWHO recommends treating hepatitis C infection with one of three antiviral combinations for 8–12 weeks. No randomised trials have compared these regimens, and high cure rates might be achievable with shorter durations of therapy. We aimed to compare sofosbuvir–daclatasvir with sofosbuvir–velpatasvir, and to evaluate potential novel treatment strategies. MethodsWe conducted a multi-arm, open-label
-
Improved hypertension care requires measurement and management in health facilities, not mass screening Lancet (IF 98.4) Pub Date : 2025-05-08 Thomas R Frieden, Renu Garg, Andrew E Moran, Paul K Whelton
Improved hypertension control can save millions of lives, but mass hypertension screening, a commonly used approach, is a barrier to progress. Although politically appealing, mass screening diverts resources from improving services in primary health care. Hypertension treatment requires ongoing, long-term care. Mass screening is inefficient: many people with hypertension are not screened or not screened
-
Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial Lancet (IF 98.4) Pub Date : 2025-05-08 Thomas Yau, Peter R Galle, Thomas Decaens, Bruno Sangro, Shukui Qin, Leonardo G da Fonseca, Hatim Karachiwala, Jean-Frederic Blanc, Joong-Won Park, Edward Gane, Matthias Pinter, Ana Matilla Pe?a, Masafumi Ikeda, David Tai, Armando Santoro, Gonzalo Pizarro, Chang-Fang Chiu, Michael Schenker, Aiwu He, Hong Jae Chon, Masatoshi Kudo
BackgroundPatients with unresectable hepatocellular carcinoma have a poor prognosis, and treatments with long-term benefits are needed. We report results from the preplanned interim analysis of the CheckMate 9DW trial assessing nivolumab plus ipilimumab versus lenvatinib or sorafenib for unresectable hepatocellular carcinoma in the first-line setting. MethodsThis open-label, randomised, phase 3 trial
-
Mapping the unseen: global prevalence of childhood sexual violence Lancet (IF 98.4) Pub Date : 2025-05-08 Elizabeth J Letourneau, Luciana C Assini-Meytin
No Abstract
-
Nivolumab plus ipilimumab in hepatocellular carcinoma Lancet (IF 98.4) Pub Date : 2025-05-08 Mathew Vithayathil, Rohini Sharma
No Abstract
-
Prevalence of sexual violence against children and age at first exposure: a global analysis by location, age, and sex (1990–2023) Lancet (IF 98.4) Pub Date : 2025-05-08 Jack Cagney, Cory Spencer, Luisa Flor, Molly Herbert, Mariam Khalil, Erin O'Connell, Erin Mullany, Flavia Bustreo, Joht Singh Chandan, Nicholas Metheny, Felicia Knaul, Emmanuela Gakidou
BackgroundMeasuring sexual violence against children (SVAC) is vital to prevention and advocacy efforts, yet existing prevalence studies present estimates for few countries. Here we estimate the prevalence of SVAC for 204 countries by age and sex, from 1990 to 2023, and also report the age at which young survivors of lifetime sexual violence first experienced sexual violence. MethodsWe reviewed publicly
-
Innovative strategies to enhance access to HCV therapy Lancet (IF 98.4) Pub Date : 2025-05-08 Hannah Roth, Andrew Aronsohn
No Abstract